SCYX SCYNEXIS INC

SCYNEXIS to Participate in Upcoming September Investor Conferences

SCYNEXIS to Participate in Upcoming September Investor Conferences

JERSEY CITY, N.J., Sept. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Officer of SCYNEXIS, will present in person at the upcoming H.C. Wainwright Annual Global Investment Conference and the Ladenburg Thalmann Annual Healthcare Conference.

Event:H.C. Wainwright 24th Annual Global Investment Conference, New York
Date:Wednesday September 14, 2022
Time:3:30 p.m. – 4:00 p.m. EDT
Format:Company presentation and 1:1 meetings
Registration:
  
Event:Ladenburg Thalmann 2022 Annual Healthcare Conference, New York
Date:Thursday, September 29, 2022
Time:12:00 p.m. – 12:25 p.m. EDT
Format:Company presentation and 1:1 meetings
Webcast:

The presentations and archived webcasts can be found on the SCYNEXIS website for 30 days following the event.

About SCYNEXIS



SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., . The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. The FDA has accepted the Company’s sNDA submission for prevention of recurrent vulvovaginal candidiasis (VVC) and assigned a PDUFA decision date of November 30, 2022. In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit .

CONTACTS:

Investors

Irina Koffler

LifeSci Advisors, LLC

646-970-4681

Media

Debbie Etchison

SCYNEXIS



EN
09/09/2022

Underlying

SCYXSCYNEXIS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCYNEXIS INC

 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the transfer of the BREXAFEMM...

November 19, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

Scynexis Announces Federal Funding of Collaboration Between Hackensack...

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation of triterpenoid antifungals (fungerps).Next-generation fungerps, in preclinical stages of development, are targeted to have enhanced pharmacological properties to treat fungal infections wh...

November 17, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Cor...

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s request to terminate the study.Following the positive SAD/MAD data results announced in September for SCY-247, its second-generation fungerp, the Company expects to initiate a Phase 1 study with the IV formulation and a Phase 2 study for the treatment of invasive candidiasis. The Company aims to...

November 5, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of ...

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasisScynexis will promptly wind-down and terminate the MARIO studyThe payment from GSK, combined with cash in hand and removal of future MARIO expenditures, extends the company’s cash runway to more than two yearsGSK remains committed to the commercialization of BREXAFEMME (ibrexafungerp tablets) JERSEY CITY, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, In...

October 15, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending D...

SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247) No safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our first-generation fungerp Safety, tolerability, and pharmacokinetic profile support the continued clinical development of SCY-247 JERSEY CITY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and dru...

September 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch